ENDRA Life Sciences (Nasdaq: NDRA)

ENDRA Life Sciences Inc. (NDRA) is a biotechnology company headquartered in the United States and founded in 2007. The company's focus is on early detection of liver disease, particularly Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100B annually. ENDRA is addressing the limitations of current diagnostic tools by developing a next-generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform, which aims to enable visualization of tissue composition, function, and temperature at the point-of-care, akin to capabilities offered by CT and MRI but at a fraction of the cost. ENDRA's recent funding includes a $8.70M post-IPO equity investment by Ascendiant Capital on April 21, 2022. The company's innovative approach to addressing the unmet needs in liver disease diagnosis and monitoring, coupled with its potential to significantly reduce healthcare costs, makes it an attractive prospect for venture capital investment. With the global burden of NAFLD projected to increase, ENDRA's efforts to broaden access to better healthcare through enhanced ultrasound technologies position it as a promising player in the biotechnology and healthcare industries. For further details, please visit www.endrainc.com.